Top Markets
#1 Black Phoenix Black Phoenix +831.35%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +29.79%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.50%
#4 Beam Beam +26.38%
#5 SAFEcoin SAFEcoin +20.76%
#6 Magma Finance Magma Finance +20.25%
#7 pipedog pipedog +19.56%
#8 PondCoin PondCoin +18.82%
#9 THORChain THORChain +16.58%
#10 Bless Bless +16.25%
Coin of the day
Black Phoenix Black Phoenix
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Metis Techbio-p Metis Techbio-p

Metis Techbio-p

7666
Rang in Aktien #6112
Metis TechBio Co., Ltd., founded in 2020 and headquartered in Beijing, China,... Metis TechBio Co., Ltd., founded in 2020 and headquartered in Beijing, China, (previously Hangzhou Jitai Pharmaceutical Technology Co., Ltd.) specializes in the advanced research and development of AI-powered nanomaterials. The company's core mission is to facilitate the delivery and application of active agents within carbon-based life forms, operating in both the Chinese Mainland and the United States. Central to its offerings is NanoForge, a comprehensive suite of interconnected technologies that includes a novel lipid library, foundational artificial intelligence models, METiSAIAgent, cutting-edge quantum chemistry and molecular dynamics simulations, and AI-driven screening platforms. Furthermore, Metis TechBio has developed specialized platforms like AiTEM, AiLNP, and AiRNA. These tools are crucial for simulating, predicting, and interpreting interactions at the nanoscale, thereby enabling the precise design, optimization, and validation of sophisticated nanomaterials and their associated payloads. The company provides its services through a three-tiered system: a foundational dry-wet data layer supported by integrated laboratory infrastructure, a model layer featuring METiS AI foundational models, and an application layer known as METiSAgentv. Metis TechBio primarily serves a diverse clientele, including pharmaceutical companies, biotechnology firms, and medical research institutions.
Aktienkurs
$1.88
Marktkapitalisierung
$2.22B
Veränderung (1 Tag)
-0.81%
Veränderung (1 Jahr)
-
Land
CN
Handel Metis Techbio-p (7666)

Kategorie

Healthcare
Umsatz von Metis Techbio-p (7666)
Umsatz im Aug 2026 TTM: 0
Laut den aktuellen Finanzberichten von Metis Techbio-p beträgt der derzeitige Umsatz des Unternehmens (TTM) 0. Im Jahr 2026 erzielte das Unternehmen einen Umsatz von 0 gleich wie dem Umsatz im Jahr 2026, der 0 betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Metis Techbio-p von 2026 bis 2026
Umsatz am Ende jedes Jahres
Jahr Umsatz ändert
Nicht genügend Daten für die angegebenen Daten.
Umsatz vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Umsatz Umsatzunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH